AbstractHypoxia is characterized as a decrease oxygen levels in tissue, represents a fundamental pathophysiological condition in the microenvironment of solid tumors. The key component of hypoxia sensing in the cell is the hypoxiainducible factor (HIF), a transcriptional activator that mediates adaptive responses to hypoxia. HIF is a heterodimer comprising an oxygenregulated asubunit (HIF1a) and a constitutively expressed bsubunit (HIF1b). HIF1 activity increases in the majority of human cancers and acts as a master transcription factor that has received the most intense attention in the field of cancer biology. The stability and activity of HIF1 are regulated by its posttranslational modifications such as hydroxylation, ubiquitination, acetylation, and phosphorylation. HIFI induces a series of genes that participate in angiogenesis, iron metabolism, glucose metabolism, and cell proliferation/survival. Some novel agents have been shown to be targeted HIF1 through a variety of molecular mechanisms and could represent a novel approach to cancer therapy.
Keywords: HypoxiaInducibleFactor1;CancerProgression; TherapeuticTarget